Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDIRECT: AFM13 in Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides
2019-001003-20Phase 2Completed
- Sponsor
- Affimed
- Start
- Jul 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acimtamig in peripheral T-cell lymphoma (PTCL) and mycosis fungoides (MF), sponsored by Affimed. Primary endpoint: Independent Review Committee-confirmed objective response rate (ORR). Started Jul 2019; status: completed.
02
Drugs
acimtamig
03
Conditions
peripheral T-cell lymphoma (PTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2019-001003-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001003-20.